{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:34:56Z","timestamp":1787927696688,"version":"build-2784847793"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,10,9]],"date-time":"2017-10-09T00:00:00Z","timestamp":1507507200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s11940-017-0478-x","type":"journal-article","created":{"date-parts":[[2017,10,9]],"date-time":"2017-10-09T01:26:05Z","timestamp":1507512365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Diagnosis and Management of Cognitive and Behavioral Changes in Dementia With Lewy Bodies"],"prefix":"10.1007","volume":"19","author":[{"given":"Babak","family":"Tousi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,9]]},"reference":[{"issue":"5","key":"478_CR1","first-page":"292","volume":"82","author":"K Kosaka","year":"1980","unstructured":"Kosaka K, Matsushita M, Oyanagi S, Mehraein P. A cliniconeurophathological study of the \u201cLewy body disease\u201d. Seishin Shinkeigaku Zasshi. 1980;82(5):292\u2013311.","journal-title":"Seishin Shinkeigaku Zasshi"},{"key":"478_CR2","unstructured":"Tousi B, Flanigan P, Khosravi M. Impaired Color Vision in Patients with DLB or Prodromal DLB. [abstract]. Mov Disord. 2017;32(2). http:\/\/www.mdsabstracts.org\/abstract\/impaired-color-vision-in-patients-with-dlbor-prodromal-dlb\/ . Accessed September 20, 2017."},{"issue":"7","key":"478_CR3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/mds.25037","volume":"27","author":"RB Postuma","year":"2012","unstructured":"Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord. 2012;27(7):913\u20136.","journal-title":"Mov Disord"},{"issue":"5","key":"478_CR4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ana.22282","volume":"69","author":"RB Postuma","year":"2011","unstructured":"Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir JY. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol. 2011;69(5):811\u20138.","journal-title":"Ann Neurol"},{"issue":"1","key":"478_CR5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"\u2022\u2022 McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88\u2013100. This guideline provides an up to date diagnostic criteria for dementia with Lewy bodies.","journal-title":"Neurology"},{"key":"478_CR6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pscychresns.2016.12.011","volume":"261","author":"Y Manabe","year":"2017","unstructured":"Manabe Y, Inui Y, Toyama H, Kosaka K. 123I-Metaiodobenzylguanidine myocardial scintigraphy with early images alone is useful for the differential diagnosis of dementia with Lewy bodies. Psychiatry Res. 2017;261:75\u20139.","journal-title":"Psychiatry Res"},{"issue":"1","key":"478_CR7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3988\/jcn.2011.7.1.19","volume":"7","author":"KW Park","year":"2011","unstructured":"Park KW, Kim HS, Cheon SM, Cha JK, Kim SH, Kim JW. Dementia with Lewy bodies versus Alzheimer\u2019s disease and Parkinson\u2019s disease dementia: a comparison of cognitive profiles. J Clin Neurol. 2011;7(1):19\u201324.","journal-title":"J Clin Neurol"},{"issue":"1","key":"478_CR8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mds.10633","volume":"19","author":"E Noe","year":"2004","unstructured":"Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y. Comparison of dementia with Lewy bodies to Alzheimer\u2019s disease and Parkinson\u2019s disease with dementia. Mov Disord. 2004;19(1):60\u20137.","journal-title":"Mov Disord"},{"issue":"2","key":"478_CR9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/jnnp.70.2.157","volume":"70","author":"J Calderon","year":"2001","unstructured":"Calderon J, Perry RJ, Erzinclioglu SW, Berrios GE, Dening TR, Hodges JR. Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2001;70(2):157\u201364.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"478_CR10","doi-asserted-by":"crossref","first-page":"153331751772581","DOI":"10.1177\/1533317517725811","volume":"1","author":"E Yamamoto","year":"2017","unstructured":"Yamamoto E, Mourany L, Colleran R, Whitman C, Tousi B. Utility of Montreal Cognitive Assessment in differentiating dementia with Lewy bodies from Alzheimer\u2019s dementia. Am J Alzheimers Dis Other Demen. 2017;1:1533317517725811.","journal-title":"Am J Alzheimers Dis Other Demen."},{"issue":"9","key":"478_CR11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp.74.9.1215","volume":"74","author":"D Aarsland","year":"2003","unstructured":"Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson\u2019s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1215\u201320.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10004","key":"478_CR12","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","volume":"386","author":"Z Walker","year":"2015","unstructured":"Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683\u201397.","journal-title":"Lancet"},{"issue":"1","key":"478_CR13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1017\/S1041610208008168","volume":"21","author":"I McKeith","year":"2009","unstructured":"McKeith I. Top cited papers in international psychogeriatrics: 1. Long-term use of rivastigmine in patients with dementia with lewy bodies: an open-label trial. Int Psychogeriatr. 2009;21(1):5. discussion 5-6","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"478_CR14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-014-0083-0","volume":"7","author":"M Ikeda","year":"2015","unstructured":"\u2022 Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015;7(1):4. This manuscript provides information regarding the first large randomized clinical trial of donepezil in dementia with Lewy bodies.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"478_CR15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13195-014-0081-2","volume":"7","author":"E Mori","year":"2015","unstructured":"Mori E, Ikeda M, Nagai R, Matsuo K, Nakagawa M, Kosaka K. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of phase III trial. Alzheimers Res Ther. 2015;7(1):5.","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"478_CR16","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"9","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson\u2019s disease dementia or dementia with lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969\u201377.","journal-title":"Lancet Neurol"},{"issue":"7","key":"478_CR17","doi-asserted-by":"crossref","first-page":"e005158","DOI":"10.1136\/bmjopen-2014-005158","volume":"4","author":"K Stubendorff","year":"2014","unstructured":"Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E. Treatment effect of memantine on survival in dementia with lewy bodies and Parkinson\u2019s disease with dementia: a prospective study. BMJ Open. 2014;4(7):e005158.","journal-title":"BMJ Open"},{"key":"478_CR18","unstructured":"Donepezil. http:\/\/www.pdr.net . Updated 2017. Accessed Sept 2017."},{"key":"478_CR19","unstructured":"Rivastigmine. http:\/\/www.pdr.net . Updated 2017. Accessed Sept 2017."},{"key":"478_CR20","first-page":"45","volume":"127","author":"F Inglis","year":"2002","unstructured":"Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl. 2002;127:45\u201363.","journal-title":"Int J Clin Pract Suppl"},{"key":"478_CR21","unstructured":"Levodopa. http:\/\/www.pdr.net . Accessed Sept 2017."},{"key":"478_CR22","unstructured":"MHRA. Citalopram 40mg\/ml oral drops, solution. www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con049076.pdf . Updated 2017. Accessed Sept 2017."},{"issue":"3","key":"478_CR23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00314594","volume":"237","author":"K Kosaka","year":"1990","unstructured":"Kosaka K. Diffuse Lewy body disease in Japan. J Neurol. 1990;237(3):197\u2013204.","journal-title":"J Neurol"},{"key":"478_CR24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.162.3.385","volume":"162","author":"H Forstl","year":"1993","unstructured":"Forstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy-body variant of Alzheimer\u2019s disease. Clinical and pathological findings. Br J Psychiatry. 1993;162:385\u201392.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"478_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.40.1.1","volume":"40","author":"L Hansen","year":"1990","unstructured":"Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer\u2019s disease: a clinical and pathologic entity. Neurology. 1990;40(1):1\u20138.","journal-title":"Neurology"},{"issue":"3 Suppl","key":"478_CR26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3233\/JAD-2006-9S347","volume":"9","author":"IG McKeith","year":"2006","unstructured":"McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with lewy bodies (DLB): report of the consortium on DLB international workshop. J Alzheimers Dis. 2006;9(3 Suppl):417\u201323.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"478_CR27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archneur.59.1.102","volume":"59","author":"H Apaydin","year":"2002","unstructured":"Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol. 2002;59(1):102\u201312.","journal-title":"Arch Neurol"},{"issue":"3","key":"478_CR28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/A:1021626420760","volume":"9","author":"CA Luis","year":"1999","unstructured":"Luis CA, Mittenberg W, Gass CS, Duara R. Diffuse Lewy body disease: clinical, pathological, and neuropsychological review. Neuropsychol Rev. 1999;9(3):137\u201350.","journal-title":"Neuropsychol Rev"},{"issue":"1","key":"478_CR29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.archger.2007.03.003","volume":"46","author":"B Borroni","year":"2008","unstructured":"Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr. 2008;46(1):101\u20136.","journal-title":"Arch Gerontol Geriatr"},{"issue":"9","key":"478_CR30","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1212\/WNL.0b013e3182a2cbd1","volume":"81","author":"BP Boot","year":"2013","unstructured":"Boot BP, Orr CF, Ahlskog JE, et al. Risk factors for dementia with lewy bodies: a case-control study. Neurology. 2013;81(9):833\u201340.","journal-title":"Neurology"},{"key":"478_CR31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13195-016-0171-4","volume":"8","author":"MH Breitve","year":"2016","unstructured":"Breitve MH, Hynninen MJ, Bronnick K, et al. A longitudinal study of anxiety and cognitive decline in dementia with lewy bodies and Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8:3.","journal-title":"Alzheimers Res Ther"},{"key":"478_CR32","unstructured":"Tousi B, Mourany L. Correlation between neuro-behavioral symptoms, cognition and gait in patients with dementia with Lewy bodies (DLB) [abstract]. Mov Disord. 2016;31(2). http:\/\/www.mdsabstracts.org\/abstract\/correlation-between-neuro-behavioralsymptoms-cognition-and-gait-in-patients-with-dementia-with-lewy-bodies-dlb\/ . Accessed September 20, 2017."},{"issue":"4","key":"478_CR33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3949\/ccjm.81a.13068","volume":"81","author":"RM Factora","year":"2014","unstructured":"Factora RM, Tousi B. Don\u2019t forget non-Alzheimer dementias. Cleve Clin J Med. 2014;81(4):243\u201354.","journal-title":"Cleve Clin J Med"},{"issue":"5","key":"478_CR34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1017\/S1041610212002189","volume":"25","author":"P Thaipisuttikul","year":"2013","unstructured":"Thaipisuttikul P, Lobach I, Zweig Y, Gurnani A, Galvin JE. Capgras syndrome in dementia with Lewy bodies. Int Psychogeriatr. 2013;25(5):843\u20139.","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"478_CR35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0278-5846(03)00040-X","volume":"27","author":"H Takahashi","year":"2003","unstructured":"Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with lewy bodies: a case series. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;27(3):549\u201353.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"17","key":"478_CR36","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","volume":"68","author":"R Kurlan","year":"2007","unstructured":"Kurlan R, Cummings J, Raman R, Thal L. Alzheimer\u2019s disease cooperative study group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356\u201363.","journal-title":"Neurology"},{"key":"478_CR37","unstructured":"Quetiapine. http:\/\/www.pdr.net . Updated 2017. Accessed Sept 2017."},{"key":"478_CR38","unstructured":"Clozapine. http:\/\/www.pdr.net . Updated 2017. Accessed Sept 2017."},{"issue":"9916","key":"478_CR39","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"\u2022 Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533\u201340. This article provides the results of the pivotal study for pimavanserine as first FDA-approved treatment for neuropsychiatric symptom of a neurodegenerative disease.","journal-title":"Lancet"},{"key":"478_CR40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/WNF.0000000000000219","volume":"40","author":"JH Friedman","year":"2017","unstructured":"Friedman JH. A retrospective study of pimavanserin use in a movement disorders clinic. Clin Neuropharmacol. 2017;40:157\u20139.","journal-title":"Clin Neuropharmacol"},{"issue":"3\u20134","key":"478_CR41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000439252","volume":"16","author":"L Chwiszczuk","year":"2016","unstructured":"Chwiszczuk L, Breitve M, Hynninen M, Gjerstad MD, Aarsland D, Rongve A. Higher frequency and complexity of sleep disturbances in dementia with lewy bodies as compared to Alzheimer\u2019s disease. Neurodegener Dis. 2016;16(3\u20134):152\u201360.","journal-title":"Neurodegener Dis"},{"issue":"7","key":"478_CR42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/gps.4389","volume":"31","author":"GJ Elder","year":"2016","unstructured":"Elder GJ, Colloby SJ, Lett DJ, et al. Depressive symptoms are associated with daytime sleepiness and subjective sleep quality in dementia with Lewy bodies. Int J Geriatr Psychiatry. 2016;31(7):765\u201370.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2 Dementia","key":"478_CR43","first-page":"435","volume":"22","author":"SN Gomperts","year":"2016","unstructured":"Gomperts SN. Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum (Minneap Minn). 2016;22(2 Dementia):435\u201363.","journal-title":"Continuum (Minneap Minn)"},{"issue":"7","key":"478_CR44","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/1533317512456450","volume":"27","author":"E Prado","year":"2012","unstructured":"Prado E, Paholpak P, Ngo M, et al. Agitation and psychosis associated with dementia with Lewy bodies exacerbated by modafinil use. Am J Alzheimers Dis Other Demen. 2012;27(7):468\u201373.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"5\u20136","key":"478_CR45","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000471507","volume":"43","author":"MI Lapid","year":"2017","unstructured":"Lapid MI, Kuntz KM, Mason SS, et al. Efficacy, safety, and tolerability of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies: a pilot study. Dement Geriatr Cogn Disord. 2017;43(5\u20136):269\u201380.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"478_CR46","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.psychres.2017.02.039","volume":"251","author":"H Kazui","year":"2017","unstructured":"Kazui H, Adachi H, Kanemoto H, et al. Effects of donepezil on sleep disturbances in patients with dementia with Lewy bodies: an open-label study with actigraphy. Psychiatry Res. 2017;251:312\u20138.","journal-title":"Psychiatry Res"},{"issue":"1","key":"478_CR47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.sleep.2014.09.011","volume":"16","author":"IR McGrane","year":"2015","unstructured":"McGrane IR, Leung JG, St Louis EK, Boeve BF. Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015;16(1):19\u201326.","journal-title":"Sleep Med"},{"issue":"5","key":"478_CR48","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/mds.27018","volume":"32","author":"EK St Louis","year":"2017","unstructured":"St Louis EK, Boeve AR, Boeve BF. REM sleep behavior disorder in Parkinson\u2019s disease and other synucleinopathies. Mov Disord. 2017;32(5):645\u201358.","journal-title":"Mov Disord"},{"issue":"1","key":"478_CR49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5664\/jcsm.27717","volume":"6","author":"RN Aurora","year":"2010","unstructured":"Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85\u201395.","journal-title":"J Clin Sleep Med"},{"key":"478_CR50","unstructured":"Clonazepam. http:\/\/www.pdr.net . Updated 2017. Accessed Sept 2017."},{"issue":"9","key":"478_CR51","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1176\/ajp.146.9.1166","volume":"146","author":"CH Schenck","year":"1989","unstructured":"Schenck CH, Milner DM, Hurwitz TD, Bundlie SR, Mahowald MW. A polysomnographic and clinical report on sleep-related injury in 100 adult patients. Am J Psychiatry. 1989;146(9):1166\u201373.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"478_CR52","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/JCP.0b013e318295fdf4","volume":"33","author":"K Kasanuki","year":"2013","unstructured":"Kasanuki K, Iseki E, Nishida Y, et al. Effectiveness of ramelteon for treatment of visual hallucinations in dementia with lewy bodies: a report of 4 cases. J Clin Psychopharmacol. 2013;33(4):581\u20133.","journal-title":"J Clin Psychopharmacol"},{"key":"478_CR53","unstructured":"Ramelteon. http:\/\/www.pdr.net . Accessed Sept 2017."},{"issue":"Pt 3","key":"478_CR54","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/brain\/awm322","volume":"131","author":"L Bonanni","year":"2008","unstructured":"Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer\u2019s disease, dementia with lewy bodies and Parkinson\u2019s disease with dementia patients with a 2-year follow-up. Brain. 2008;131(Pt 3):690\u2013705.","journal-title":"Brain"},{"issue":"1","key":"478_CR55","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/jpet.109.160994","volume":"332","author":"HA Al-Shamma","year":"2010","unstructured":"Al-Shamma HA, Anderson C, Chuang E, et al. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther. 2010;332(1):281\u201390.","journal-title":"J Pharmacol Exp Ther"},{"key":"478_CR56","unstructured":"Wen W, Friedhoff L, Kishnani K, Ramaswamy S, Piscitelli S, Sanchez M, Shanahan W. Safety of nelotanserin in a randomized placebo-controlled phase 2 study [abstract]. Mov Disord. 2016;31(2). http:\/\/www.mdsabstracts.org\/abstract\/safety-of-nelotanserin-in-a-randomizedplacebo-controlled-phase-2-study . Accessed September 20, 2017."},{"issue":"7","key":"478_CR57","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jalz.2015.08.154","volume":"11","author":"I Lombardo","year":"2015","unstructured":"Lombardo I, Ramaswamy G, Piscitelli S, Friedhoff L. The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer\u2019s disease: completer analysis of a phase 2b study. Alzheimer\u2019s & Dementia: The Journal of the Alzheimer\u2019s Association. 2015;11(7):332.","journal-title":"Alzheimer\u2019s & Dementia: The Journal of the Alzheimer\u2019s Association"},{"issue":"5","key":"478_CR58","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/jcpt.12179","volume":"39","author":"MH Chagas","year":"2014","unstructured":"Chagas MH, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: a case series. J Clin Pharm Ther. 2014;39(5):564\u20136.","journal-title":"J Clin Pharm Ther"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-017-0478-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0478-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0478-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T22:33:09Z","timestamp":1603060389000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-017-0478-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,9]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["478"],"URL":"https:\/\/doi.org\/10.1007\/s11940-017-0478-x","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,9]]},"article-number":"42"}}